|Dr. Ali Fattaey Ph.D.||716.43k||N/A||52|
|Mr. James E. Dentzer||470.35k||N/A||50|
|Dr. David Tuck M.D.||466.28k||N/A||65|
|Mr. Daniel R. Passeri MSc., J.D.||N/A||N/A||56|
|Mr. Mark W. Noel||N/A||N/A||58|
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. The company develops CUDC-907, an oral small molecule inhibitor of histone deacetylase and phosphatidylinositol-3-kinase enzymes, which is in Phase II clinical trials for relapsed or refractory diffuse large B-cell lymphoma, as well as in Phase I clinical trials for patients with solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trials in patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in preclinical stage for the treatment of hematologic cancers; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers. It is also developing Erivedge, an orally-administered small molecule hedgehog pathway inhibitor for advanced basal cell carcinoma, idiopathic pulmonary fibrosis, and myelofibrosis. The company has collaboration agreement with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and collaboration and license agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge. Curis, Inc. was founded in 2000 and is headquartered in Lexington, Massachusetts.
Curis, Inc.’s ISS Governance QualityScore as of October 15, 2017 is 7. The pillar scores are Audit: 2; Board: 5; Shareholder Rights: 8; Compensation: 6.